Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | COXFA4 | O00483 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | ODC1 | P11926 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prococene Ii SCHEMBL119925 | 0.81 | ODC1 (0.54) | ALDH1A1CYP3A4HPGDTDP1HIF1A | |
| SCHEMBL546770 | 0.81 | ALDH1A1 (0.48) | ALDH1A1CYP3A4HPGDTDP1COXFA4 | |
| Demethylencecalin SCHEMBL29903823 | 0.81 | ALDH1A1 (1.00) | ALDH1A1CYP3A4HPGDTDP1PTPN1 | |
| Demethylencecalin SCHEMBL31238098 | 0.81 | ALDH1A1 (1.00) | ALDH1A1CYP3A4HPGDTDP1PTPN1 | |
| SCHEMBL29404075 | 0.79 | ALDH1A1 (0.54) | ALDH1A1CYP3A4HPGDTDP1HIF1A | |
| SCHEMBL545855 | 0.79 | ALDH1A1 (0.54) | ALDH1A1CYP3A4HPGDTDP1HIF1A | |
| SCHEMBL11012720 | 0.78 | TLR3 (0.48) | COXFA4HIF1AODC1 | |
| SCHEMBL8881498 | 0.76 | ODC1 (0.49) | HIF1AODC1 | |
| SCHEMBL10508119 | 0.75 | ODC1 (0.46) | HIF1AODC1 | |
| SCHEMBL8882520 | 0.75 | ODC1 (0.49) | ALDH1A1CYP3A4HPGDTDP1ODC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | YUZU LV LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12458653-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2025-11-04 | — | — | US | disclosed |
| US-12427176-B2 | Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products | RIZUN NODARI (US) | 2025-09-30 | — | — | US | disclosed |
| US-12303488-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2025-05-20 | — | — | US | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| EP-4417252-A2 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | Yuzu LV LLC (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20240216457-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240216456-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240207342-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-06-27 | — | — | US | disclosed |
| US-20230293480-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | YUZU LV LLC | 2023-09-21 | — | — | US | disclosed |
| US-20230293555-A1 | COMPOSITIONS COMPRISING CANNABIDIOL AND FLAVANONES | YUZU LV LLC | 2023-09-21 | — | — | US | disclosed |
| US-11684604-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220387537-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2022-12-08 | — | — | US | disclosed |
| US-20210023044-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | YUZU LV LLC | 2021-01-28 | — | — | US | disclosed |
| US-20170042823-A1 | CO-ENCAPSULATION OF ANTIMICROBIALS AND ADJUVANTS IN NANOCARRIERS | UNIV PRINCETON (US) | 2017-02-16 | — | — | US | disclosed |
| WO-2009134112-A1 | PHARMACEUTICAL FORMULATION THAT COMPRISES A BLEACHED EXTRACT OF AGERATINA PICHINCHENSIS FOR TREATING ONYCHOMYCOSIS | ROMERO CERECERO OFELIA (MX) | 2009-11-05 | — | — | WO | disclosed |
| WO-2008100977-A2 | CARBAMATES THERAPEUTIC RELEASE AGENTS AS AMIDASE INHIBITORS | N.V. ORGANON (NL) | 2008-08-21 | — | — | WO | disclosed |
| EP-0028449-B1 | CHROMANOL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION COMPRISING THEM | BEECHAM GROUP PLC (GB) | 1983-07-20 | — | — | EP | disclosed |
| EP-0028449-A1 | Chromanol derivatives, a process for their preparation and a pharmaceutical composition comprising them | BEECHAM GROUP PLC (GB) | 1981-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11684604-B2 | Cannabis based therapeutic and method of use | CNR2, CNR1, OPRK1 | ALDH1A1 3206/4885CYP3A4 2613/4885HPGD 1556/4885 |
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | CNR1, CNR2, OPRM1 | ALDH1A1 1420/4885CYP3A4 1136/4885HPGD 696/4885 |
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | TRPV1, SOST, RUNX1 | ALDH1A1 4768/4885CYP3A4 1979/4885HPGD 1580/4885 |
| US-20210023044-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | CNR2, CNR1, OPRK1 | ALDH1A1 3206/4885CYP3A4 2613/4885HPGD 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.